Daily Cardiology Research Analysis
Analyzed 229 papers and selected 3 impactful papers.
Summary
Analyzed 229 papers and selected 3 impactful articles.
Selected Articles
1. Polypill for heart failure with reduced ejection fraction: the POLY-HF randomized trial.
In an open-label randomized trial of 212 patients with HFrEF, a once-daily polypill improved LVEF by 3.3 percentage points at 6 months versus enhanced usual care and reduced HF hospitalizations/ED visits by 60%. Pharmacologic adherence was significantly higher with the polypill, and tolerability was favorable.
Impact: Demonstrates a pragmatic strategy to overcome underuse of guideline therapies by improving adherence and clinical outcomes in a largely underserved population.
Clinical Implications: A fixed-dose HFrEF polypill could streamline initiation and titration, improve adherence, and reduce acute care use. Health systems may consider polypill programs alongside renin–angiotensin inhibition, especially in underserved populations.
Key Findings
- Primary endpoint met: between-group LVEF difference +3.3 percentage points by cardiac MRI at 6 months (95% CI 0.2–6.4; P=0.039).
- HF hospitalizations/ED visits reduced by 60% with polypill (adjusted rate ratio 0.40; 95% CI 0.18–0.88; P=0.024).
- Higher pharmacologic adherence with polypill (79% vs 54%; P=0.001) and fewer adverse events than enhanced usual care.
Methodological Strengths
- Randomized design with cardiac MRI assessment of primary endpoint.
- Objective adherence measurement using drug blood concentrations.
Limitations
- Open-label, two-center design limits blinding and generalizability.
- Short-term (6-month) primary endpoint; not powered for mortality.
Future Directions: Larger, multicenter pragmatic and cost-effectiveness trials with longer follow-up to assess mortality, quality of life, and scalability across diverse health systems.
Heart failure with reduced ejection fraction carries a poor prognosis. Although guideline-directed medical therapy reduces morbidity and mortality, its real-world utilization is low. Accordingly, we conducted an open-label randomized trial (POLY-HF) at two centers enrolling a predominantly underserved population to test whether a polypill strategy improves cardiac function in heart failure. Adults with heart failure and left ventricular ejection fraction ≤40% were randomized to a once-daily polypill containing metoprolol succinate (25/50/100/150 mg), spironolactone 12.5 mg and empagliflozin 10 mg, or rapid uptitration of individual guideline-directed medical therapy medications ('enhanced usual care'). Participants also continued treatment with a renin-angiotensin system inhibitor or sacubitril/valsartan as a separate pill. The primary endpoint was ejection fraction as assessed by cardiac magnetic resonance imaging at 6 months. Secondary endpoints included clinical outcomes and adherence. We randomized 212 patients (median age 54 years, 22% female, 54% Black). Follow-up magnetic resonance imaging data were available for 187 (88%) participants who were included in the modified intention-to-treat analysis. Polypill treatment was associated with greater improvement in ejection fraction compared to enhanced usual care (between-group difference, 3.3 percentage points, 95% confidence interval, 0.2-6.4; P = 0.039), meeting the primary outcome. Individuals randomized to the polypill also had a 60% lower rate of heart failure hospitalizations or emergency department visits (adjusted rate ratio, 0.40; 95% confidence interval, 0.18-0.88; P = 0.024). Adherence, assessed by blood concentrations of metoprolol and spironolactone, was higher with polypill treatment than with enhanced usual care (79% versus 54%, P = 0.001). The polypill was well tolerated, with fewer adverse events with polypill treatment as compared to enhanced usual care. A polypill for heart failure was associated with a significant improvement in cardiac function as compared with enhanced usual care. ClinicalTrials.gov registration: NCT04633005 .
2. HIF1α Attenuates Doxorubicin-Induced Cardiotoxicity by Activating TEX264-Associated ER-phagy.
In preclinical DIC models, stabilizing HIF1α (e.g., with FG4592) reduced systolic dysfunction, fibrosis, and apoptosis by transcriptionally activating the ER-phagy receptor TEX264, thereby enhancing ER-phagy flux. Loss of HIF1α abrogated protection, positioning the HIF1α–TEX264 axis as a central survival pathway and actionable target in doxorubicin cardiotoxicity.
Impact: Identifies a druggable ER-phagy pathway for preventing anthracycline cardiotoxicity with a clinically available HIF1α stabilizer, offering immediate translational potential in cardio-oncology.
Clinical Implications: Suggests repurposing HIF1α stabilization (e.g., FG4592/roxadustat) to mitigate cardiotoxicity in patients receiving doxorubicin, warranting early-phase clinical trials with cardiac safety and efficacy endpoints.
Key Findings
- HIF1α stabilization with FG4592 alleviated doxorubicin-induced systolic dysfunction, fibrosis, and apoptosis in vivo.
- HIF1α directly activated transcription of TEX264, enhancing ER-phagy flux; protection was abolished by HIF1α knockout.
- A biphasic HIF1α expression pattern characterized DIC progression; targeting the HIF1α–TEX264 axis restored adaptive ER-phagy.
Methodological Strengths
- Integrated in vitro and in vivo models with genetic loss/gain and pharmacologic modulation of HIF1α
- Mechanistic validation via chromatin immunoprecipitation and promoter activity assays linking HIF1α to TEX264
Limitations
- Preclinical models; absence of human clinical data
- Potential off-target and systemic effects of HIF1α stabilization not evaluated in cancer-treated patients
Future Directions: Conduct phase 1/2 trials testing HIF1α stabilization to prevent anthracycline cardiotoxicity, incorporate ER-phagy biomarkers (e.g., circulating TEX264 signatures), and assess oncologic safety.
BACKGROUND: The clinical utility of doxorubicin, a potent chemotherapeutic agent, is severely limited by its dose-dependent cardiotoxicity. Hypoxia-inducible factor 1α (HIF1α) is a key regulator of cardiovascular adaptation, but its role and mechanism in doxorubicin-induced cardiotoxicity (DIC) remain unclear. METHODS: Using in vitro (AC16 cells) and in vivo (mouse) models of DIC, we used genetic (knockout, knockdown) and pharmacological (FG4592) approaches to modulate HIF1α. Cardiac function, apoptosis, endoplasmic reticulum (ER) morphology, and ER-phagy flux were assessed. Molecular mechanisms were investigated using chromatin immunoprecipitation and promoter activity assays. RESULTS: HIF1α exhibited a dynamic, biphasic expression pattern during DIC progression. Stabilization of HIF1α by FG4592 alleviated doxorubicin-induced cardiac dysfunction, atrophy, fibrosis, and apoptosis, whereas HIF1α knockout exacerbated these injuries. The protective effects of FG4592 were strictly dependent on HIF1α. Mechanistically, HIF1α transcriptionally activated the ER-phagy receptor gene testis-expressed protein 264 ( CONCLUSIONS: This study identifies a novel HIF1α/TEX264/ER-phagy axis that is suppressed in DIC and is central to cardiomyocyte survival. Targeting this pathway, particularly with the clinically available HIF1α stabilizer FG4592, represents a promising therapeutic strategy against DIC.
3. Endomyocardial Gremlin-1 is associated with structural remodeling and adverse clinical outcomes in non-ischemic cardiomyopathy.
In 703 NICM patients evaluated with standardized EMB and long-term follow-up (up to 15 years), endomyocardial Gremlin-1 was linked to fibrosis, adverse remodeling, reduced LV function, and independently predicted mortality and ICD outcomes. Adding Gremlin-1 improved long-term risk models, highlighting a fibroinflammatory biomarker with prognostic value.
Impact: Identifies a tissue-derived biomarker with cross-sectional mechanistic correlates and robust long-term prognostic utility, potentially informing risk stratification beyond conventional imaging and clinical indices.
Clinical Implications: EMB-derived Gremlin-1 could refine risk stratification in NICM, guiding surveillance intensity and device therapy decisions; assay standardization and external validation are prerequisite for adoption.
Key Findings
- Higher endomyocardial Gremlin-1 associated with increased fibrosis, adverse remodeling, and reduced LV function.
- Myocardial and circulating Gremlin-1 independently predicted all-cause and CV mortality, ICD implantation, and appropriate ICD therapies.
- Inclusion of Gremlin-1 significantly improved long-term prognostic models; ML phenotyping identified Gremlin-1 as a key predictive feature.
Methodological Strengths
- Large, prospective cohort with standardized multimodal EMB analysis.
- Long-term follow-up (up to 15 years) with clinically relevant endpoints.
Limitations
- Observational design precludes causal inference.
- Generalizability and assay standardization require external, multicenter validation.
Future Directions: External validation cohorts, assay harmonization, and interventional studies testing Gremlin-1–guided management pathways.
BACKGROUND: Risk stratification in non-ischemic cardiomyopathies (NICM) remains challenging despite guideline-based phenotypic classification using multimodal diagnostics including endomyocardial biopsy (EMB). We aimed to identify EMB-derived histological and molecular markers that improve phenotypic characterization and long-term risk stratification in patients with NICM. METHODS: In this prospective cohort study, 703 consecutive patients with symptomatic NICM underwent standardized multimodal evaluation, including clinical assessment, cardiac imaging, and endomyocardial biopsy. Biopsy specimens were analyzed using histology, immunohistochemistry, and targeted myocardial mRNA profiling. Associations between endomyocardial markers, and fibroinflammatory remodeling, imaging parameters, and molecular signatures were assessed cross-sectionally. Long-term prognostic relevance was evaluated using survival and multivariable prediction analyses during follow-up of up to fifteen years for all-cause mortality, cardiovascular mortality, implantable cardioverter-defibrillator (ICD) implantation, and appropriate ICD discharge. RESULTS: Elevated myocardial Gremlin-1 expression was associated with increased fibrosis, adverse cardiac remodelling, reduced left ventricular function, and enrichment of pro-fibrotic and inflammatory mRNA signalling pathways. Myocardial and circulating Gremlin-1 expression was independently associated with all-cause and cardiovascular mortality, and ICD implantation and discharge. Machine learning-based phenotyping using histological EMB data identified Gremlin-1 as a key predictive feature of poor prognosis. Incorporation of Gremlin-1 into predictive models significantly improved long-term cardiovascular risk stratification in NICM patients. CONCLUSION: Our results unveil that Gremlin-1 is associated with inflammation and cardiac remodelling in patients with NICM, and patients with Gremlin-1 Non-ischemic cardiomyopathy (NICM) refers to diseases in which the heart muscle becomes abnormal and unable to pump effectively, without being caused by blocked coronary arteries. Predicting which patients will develop serious complications remains difficult using current clinical tests. We examined whether information from small heart tissue samples could improve long-term risk prediction. We analysed 703 NICM patients who underwent comprehensive clinical assessment and endomyocardial biopsy. Heart tissue was assessed for markers of inflammation and scarring, including the protein Gremlin-1, and patients were followed for up to fifteen years for major cardiovascular outcomes. Higher Gremlin-1 expression and circulating Gremlin-1 were associated with scarring, reduced heart function, and increased risk of adverse outcomes. These findings suggest that tissue-based biomarkers including Gremlin-1 may support more accurate risk stratification and personalized management in NICM.